ACTO

SEPTEMBER 11, 2024

“The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. For more information on the critical gap in pharma omnichannel engagement, read the eBook. We’re excited to see ACTO driving this transformation in the industry.”

Science 52

Science Pharma Companies Production Marketing 52

Agency IQ

JUNE 7, 2024

This requirement was included in the section of the bill that expanded FDA authority for BIMO inspections, including allowing it access to electronic information and expanding the types of facilities subject to BIMO inspections.

FDA 40

FDA Compliance Regulations Production 40

Advarra

AUGUST 16, 2022

The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drug research and development. The impact was clear: Between 1983 and 2020, FDA approved 599 orphan drugs.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Pharma Data

JANUARY 26, 2021

Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients, and it has also been granted authorizations in several additional countries. For more information about the use of bamlanivimab in the U.S., The webcast information is available here.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

NOVEMBER 10, 2020

For more information, please visit: www.innoventbio.com. Liu mentioned that he will utilize his knowledge, past experience and worldwide network to lead Innovent into the new decade with even better achievement and grow the company into a truly global first class biopharmaceutical company. View original content to download multimedia: [link].

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Codon

JANUARY 21, 2024

It introduced concepts like informed consent and risk/benefit analysis for clinical studies. I think there was still worthwhile information that came out of COVID challenge models, and there's plenty of future value, especially if we work on a broad-spectrum coronavirus family vaccine of some sort. That's what Josh was getting at.

Vaccine 120

Vaccine Trials Disease Treatment 120

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy. And ACTIV has indeed moved at unprecedented speed since its launch.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52

Sygnature Discovery

SEPTEMBER 14, 2023

Sygnature Discovery is delighted to announce that its customer, River BioMedics , has raised an additional €2M in seed funding to continue its life-saving cardiovascular drug research. For further information, visit www.riverbiomedics.com

Small Molecule 52

Small Molecule Assay Development Disease Drug Research 52

Agency IQ

AUGUST 11, 2023

In a study of more than 12,000 small molecule drugs , researchers found 40.4% This means that entire classes of critical drugs (like ACE inhibitors and beta blockers) containing secondary or tertiary amine moieties in their API molecular structures are technically nitrosamine precursors. Read below for more information on this.

FDA 40

FDA Science Production Regulations 40

Agency IQ

AUGUST 2, 2024

For example, on July 25, the Hungarian presidency hosted an informal meeting of health ministers to discuss health issues, such as mitigating the effect of cardiovascular diseases and implementing the European Health Data Space (EHDS).

Regulations 40

Regulations Clinical Trials Production Trials 40

Agency IQ

NOVEMBER 27, 2023

These API-derived nitrosamines are referred to as Nitrosamine Drug Substance Related Impurities (NDSRIs) and represent an unprecedented development with manufacturing, quality, and product safety implications. In a study of more than 12,000 small molecule drugs , researchers found 40.4%

Regulations 40

Regulations Production FDA Packaging 40

Drug Target Review

FEBRUARY 11, 2025

New era in drug research: data access and NGS The 1990s and 2000s marked a turning point in the drug development landscape, facilitated by a combination of cultural and technological factors that enabled regulatory changes, technological innovations and methodological advances.

Drug Development 59

Drug Development Bioinformatics Small Molecule Drugs 59